Neurosense Therapeutics Ltd
NRSN
View Detailed Chart
0.810USD
-0.008-1.00%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
19.93MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.00%
5 Days
-8.99%
1 Month
-24.30%
6 Months
-65.53%
Year to Date
-32.50%
1 Year
-40.44%
View Detailed Chart
TradingKey Stock Score of Neurosense Therapeutics Ltd
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neurosense Therapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
10.167
Target Price
+926.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Neurosense Therapeutics Ltd Highlights
StrengthsRisks
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Undervalued
The company’s latest PE is -3.16, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 450.04K shares, decreasing 77.73% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 0.00 shares of this stock.
Neurosense Therapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neurosense Therapeutics Ltd Info
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Ticker SymbolNRSN
CompanyNeurosense Therapeutics Ltd
CEOBen-Noon (Alon)
Websitehttps://www.neurosense-tx.com/
FAQs
What is the current price of Neurosense Therapeutics Ltd (NRSN)?
The current price of Neurosense Therapeutics Ltd (NRSN) is 0.810.
What is the symbol of Neurosense Therapeutics Ltd?
The ticker symbol of Neurosense Therapeutics Ltd is NRSN.
What is the 52-week high of Neurosense Therapeutics Ltd?
The 52-week high of Neurosense Therapeutics Ltd is 2.600.
What is the 52-week low of Neurosense Therapeutics Ltd?
The 52-week low of Neurosense Therapeutics Ltd is 0.806.
What is the market capitalization of Neurosense Therapeutics Ltd?
The market capitalization of Neurosense Therapeutics Ltd is 19.93M.
What is the net income of Neurosense Therapeutics Ltd?
The net income of Neurosense Therapeutics Ltd is -10.21M.
Is Neurosense Therapeutics Ltd (NRSN) currently rated as Buy, Hold, or Sell?
According to analysts, Neurosense Therapeutics Ltd (NRSN) has an overall rating of Buy, with a price target of 10.167.
What is the Earnings Per Share (EPS TTM) of Neurosense Therapeutics Ltd (NRSN)?
The Earnings Per Share (EPS TTM) of Neurosense Therapeutics Ltd (NRSN) is -0.361.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
